InSphero AG

Company founded: June 2010

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 7 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow.
InSphero's microtissues have shown to be more accurate in predicting compound efficacy and drug-induced toxicology by customers around the world. Most recently, the US/UK-based company Cyprotex, a global leader in toxicology testing, has signed a strategic deal with InSphero to offer commercial screening services based on InSphero's 3D microtissues.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich and was recognized for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.

Milestones / News

	06.09.2012 Cyprotex Ltd. signs strategic deal to use InSphero microtissues
	28.08.2012 InSphero closes strategic marketing partnerships with Perkin Elmer, Promega and Integra
	24.07.2012 InSphero receives grants from CTI and EU to develop new 3D microtissues with its partners (incl. AstraZeneca and others)
	23.04.2012 InSphero hires two sales managers in the US
	17.01.2012 InSphero receives ISO 9001 certification to facilitate its business with big pharma
	31.12.2011 InSphero triples its turnover in 2011
	19.09.2011 Global top-10 cosmetics company closes exclusive supply deal with InSphero
	30.08.2010 1.8 MILLIONEN FRANKEN FÜR INSPHERO